Longitudinal changes in estimated glomerular filtration rates in chronic hepatitis B patients treated with Tenofovir Alafenamide <i>vs</i> Entecavir
The kidney safety profile of TAF among treatment-naïve individuals with CHB was comparable to that of ETV, without significant difference in developing CKD. Stratified analyses further revealed that TAF demonstrated superior kidney benefits compared to ETV specifically in males or patients aged over 35 years.
Authors
- Fang Huang (ORCID: https://orcid.org/0000-0002-3429-003X)
- Hui Zeng (ORCID: https://orcid.org/0000-0002-7141-7060)
- Qiang Wu (ORCID: https://orcid.org/0000-0003-3841-3591)
- Changxiang Lai
- Juan Meng (ORCID: https://orcid.org/0000-0003-0143-9819)
- Fang Wang (ORCID: https://orcid.org/0000-0001-7687-2700)
- Lina Zhang
- Xuan Li (ORCID: https://orcid.org/0009-0004-1337-3049)
- Fengjuan Chen (ORCID: https://orcid.org/0000-0002-1663-4812)
Institutions
- Shenzhen Third People’s Hospital (CN)
Publication Details
- Journal
- PeerJ
- Published
- 2025-08-26
- DOI
- https://doi.org/10.7717/peerj.19901
- Citations
- 2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71